

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A cell growth-suppressing agent comprising any one of (a) to (c) as an active ingredient:
  - (a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;
  - (b) a DNA encoding the double-stranded RNA of (a); and
  - (c) a vector into which the DNA of (b) has been inserted.
2. (Original) The cell growth-suppressing agent of claim 1, wherein the double-stranded RNA comprises an RNA complementary to a 17AA site of a WT1 gene transcript, and an RNA complementary to said RNA.
3. (Original) The cell growth-suppressing agent of claim 1, wherein the double-stranded RNA comprises an RNA complementary to the nucleotide sequence of SEQ ID NO: 1 present in a 17AA site of a WT1 gene transcript, and an RNA complementary to said RNA.
4. (Original) The cell growth-suppressing agent of claim 1, wherein the double-stranded RNA comprises the pair of the nucleotide sequence of SEQ ID NO: 1 and the nucleotide sequence of SEQ ID NO: 2.

5. (Original) The cell growth-suppressing agent of claim 1, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.

6. (Currently Amended) The cell growth-suppressing agent of ~~any one of claims 1 to 5~~ claim 1, wherein the agent targets a cancer cell.

7. (Currently Amended) The cell growth suppressing agent of ~~any one of claims 1 to 5~~ claim 1, wherein the agent targets any one of a fibrosarcoma cell, colon cancer cell, leukemia cell, and gastric cancer cell.

8. (Original) A cell death-inducing agent comprising any one of (a) to (c) as an active ingredient:

(a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;

(b) a DNA encoding the double-stranded RNA of (a); and

(c) a vector into which the DNA of (b) has been inserted.

9. (Original) The cell death-inducing agent of claim 8, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.

10. (Currently Amended) The cell death-inducing agent of claim 8 ~~or 9~~, wherein the agent induces cell death through mitochondria.

11. (Currently Amended) The cell death-inducing agent of ~~any one of claims 8 to 10~~ claim 8, wherein the agent targets a cancer cell.

12. (Currently Amended) The cell death-inducing agent of ~~any one of claims 8 to 10~~ claim 8, wherein the agent targets any one of a fibrosarcoma cell, colon cancer cell, leukemia cell, and gastric cancer cell.

13. (Original) An agent that enhances cancer cell sensitivity to an anticancer agent, wherein the agent comprises any one of (a) to (c) as an active ingredient:

(a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;

(b) a DNA encoding the double-stranded RNA of (a); and

(c) a vector into which the DNA of (b) has been inserted.

14. (Original) The agent of claim 13, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.

15. (Original) An agent that enhances cancer cell sensitivity to a cell death-inducing agent, wherein the agent comprises any one of (a) to (c) as an active ingredient:

(a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;

(b) a DNA encoding the double-stranded RNA of (a); and

(c) a vector into which the DNA of (b) has been inserted.

16. (Original) The agent of claim 15, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.

17. (Original) An agent that eliminates mitochondrial membrane potential in a cancer cell, wherein the agent comprises any one of (a) to (c) as an active ingredient:

(a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;

(b) a DNA encoding the double-stranded RNA of (a); and

(c) a vector into which the DNA of (b) has been inserted.

18. (Original) The agent of claim 17, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.

19. (Original) An agent that enhances cytochrome c release into cytoplasm, wherein the agent comprises any one of (a) to (c) as an active ingredient:

(a) a double-stranded RNA comprising an RNA complementary to a WT1 gene transcript, and an RNA complementary to said RNA;

(b) a DNA encoding the double-stranded RNA of (a); and

(c) a vector into which the DNA of (b) has been inserted.

20. (Original) The agent of claim 19, wherein the double-stranded RNA comprises an RNA encoded by the DNA of any one of (a) to (c), and an RNA complementary to said RNA:

(a) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16;

(b) a DNA that hybridizes under stringent conditions with a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 9, 12, 14, and 16; and

(c) a DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 11, 13, 15, and 17.